These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 34558756)

  • 21. Efficacy of tocilizumab in the treatment of COVID-19: An umbrella review.
    Rezaei Tolzali MM; Noori M; Shokri P; Rahmani S; Khanzadeh S; Nejadghaderi SA; Fazlollahi A; Sullman MJM; Singh K; Kolahi AA; Arshi S; Safiri S
    Rev Med Virol; 2022 Nov; 32(6):e2388. PubMed ID: 36029180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tocilizumab for COVID-19: A systematic review and meta-analysis of randomized controlled trials.
    Boppana TK; Mittal S; Madan K; Mohan A; Hadda V; Guleria R
    Monaldi Arch Chest Dis; 2022 Feb; 92(4):. PubMed ID: 35130679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anakinra or tocilizumab for prevention of COVID-19 death? A big dilemma.
    Patoulias D; Dimosiari A; Michailidis T
    Eur J Intern Med; 2021 Aug; 90():107-108. PubMed ID: 34158235
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm.
    Narain S; Stefanov DG; Chau AS; Weber AG; Marder G; Kaplan B; Malhotra P; Bloom O; Liu A; Lesser ML; Hajizadeh N;
    Chest; 2021 Mar; 159(3):933-948. PubMed ID: 33075378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab.
    Langer-Gould A; Smith JB; Gonzales EG; Castillo RD; Figueroa JG; Ramanathan A; Li BH; Gould MK
    Int J Infect Dis; 2020 Oct; 99():291-297. PubMed ID: 32768693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systematic review and meta-analysis of tocilizumab in persons with coronavirus disease-2019 (COVID-19).
    Chen CX; Hu F; Wei J; Yuan LT; Wen TM; Gale RP; Liang Y
    Leukemia; 2021 Jun; 35(6):1661-1670. PubMed ID: 34002026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decreased Mortality in Coronavirus Disease 2019 Patients Treated With Tocilizumab: A Rapid Systematic Review and Meta-analysis of Observational Studies.
    Malgie J; Schoones JW; Pijls BG
    Clin Infect Dis; 2021 Jun; 72(11):e742-e749. PubMed ID: 32964913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial.
    Sundén-Cullberg J; Chen P; Häbel H; Skorup P; Janols H; Rasmuson J; Niward K; Östholm Balkhed Å; Chatzidionysiou K; Asgeirsson H; Blennow O; Parke Å; Svensson AK; Muvva JR; Ljunggren HG; ; Horne AC; Ådén U; Henter JI; Sönnerborg A; Vesterbacka J; Nowak P; Lampa J
    PLoS One; 2023; 18(12):e0295838. PubMed ID: 38157348
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
    Antwi-Amoabeng D; Kanji Z; Ford B; Beutler BD; Riddle MS; Siddiqui F
    J Med Virol; 2020 Nov; 92(11):2516-2522. PubMed ID: 32436994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation.
    Della-Torre E; Lanzillotta M; Campochiaro C; Cavalli G; De Luca G; Tomelleri A; Boffini N; De Lorenzo R; Ruggeri A; Rovere-Querini P; Castagna A; Landoni G; Tresoldi M; Ciceri F; Zangrillo A; Dagna L
    Front Immunol; 2021; 12():675678. PubMed ID: 33995419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab.
    Figuero-Pérez L; Olivares-Hernández A; Escala-Cornejo RA; Terán-Brage E; López-Gutiérrez Á; Cruz-Hernández JJ
    Reumatol Clin (Engl Ed); 2021 Dec; 17(10):559-561. PubMed ID: 34823820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of tocilizumab in COVID-19: A review of the current evidence.
    Alam W; Bizri AR
    Sci Prog; 2021; 104(3):368504211030372. PubMed ID: 34236264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tocilizumab in Hospitalized Patients with COVID-19: A Meta Analysis of Randomized Controlled Trials.
    Selvaraj V; Khan MS; Bavishi C; Dapaah-Afriyie K; Finn A; Lal A; Mylonakis E
    Lung; 2021 Jun; 199(3):239-248. PubMed ID: 34050796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tocilizumab and COVID-19: a meta-analysis of 2120 patients with severe disease and implications for clinical trial methodologies.
    Sarfraz A; Sarfraz Z; Sarfraz M; Aftab H; Pervaiz Z
    Turk J Med Sci; 2021 Jun; 51(3):890-897. PubMed ID: 33244947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy of anakinra compared to standard care of treatment for COVID-19: a meta-analysis.
    Malık H; Bınt Abdul Jabbar H; Latıf F; Sarfraz A; Sarfraz Z; Sarfraz M
    Turk J Med Sci; 2022 Jun; 52(3):547-553. PubMed ID: 36326309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of tocilizumab and sarilumab alone or in combination with corticosteroids for covid-19: systematic review and network meta-analysis.
    Zeraatkar D; Cusano E; Martínez JPD; Qasim A; Mangala S; Kum E; Bartoszko JJ; Devji T; Agoritsas T; Guyatt G; Izcovich A; Khamis AM; Lamontagne F; Rochwerg B; Vandvik P; Brignardello-Petersen R; Siemieniuk RAC
    BMJ Med; 2022; 1(1):e000036. PubMed ID: 36936570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically lll COVID-19 Patients.
    Karakike E; Dalekos GN; Koutsodimitropoulos I; Saridaki M; Pourzitaki C; Papathanakos G; Kotsaki A; Chalvatzis S; Dimakopoulou V; Vechlidis N; Paramythiotou E; Avgoustou C; Ioakeimidou A; Kouriannidi E; Komnos A; Neou E; Rovina N; Stefanatou E; Milionis H; Nikolaidis G; Koutsoukou A; Damoraki G; Dimopoulos G; Zoumpos V; Eugen-Olsen J; Akinosoglou K; Gatselis NK; Koulouras V; Gkeka E; Markou N; Netea MG; Giamarellos-Bourboulis EJ
    J Innate Immun; 2022; 14(3):218-228. PubMed ID: 34852352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between tocilizumab treatment of hyperinflammatory patients with COVID-19 in a critical care setting and elevated incidence of hospital-acquired bacterial and invasive fungal infections.
    Minihan B; McAuliffe E; Powell J; Wong SL; Wilkie K; Murphy C; Maher A; Power L; O'Connell NH; Dunne CP
    J Hosp Infect; 2022 Aug; 126():29-36. PubMed ID: 35472487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beneficial and harmful outcomes of tocilizumab in severe COVID-19: A systematic review and meta-analysis.
    Rubio-Rivas M; Forero CG; Mora-Luján JM; Montero A; Formiga F; Homs NA; Albà-Albalate J; Sánchez L; Rello J; Corbella X
    Pharmacotherapy; 2021 Nov; 41(11):884-906. PubMed ID: 34558742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of tocilizumab versus standard care/placebo in patients with COVID-19; a systematic review and meta-analysis of randomized clinical trials.
    Vela D; Vela-Gaxha Z; Rexhepi M; Olloni R; Hyseni V; Nallbani R
    Br J Clin Pharmacol; 2022 May; 88(5):1955-1963. PubMed ID: 34713921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.